Manuscript

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on: 
torsdag, maj 9, 2024
Brain, Coccidioides, Inflammation, Aspergillosis, Amphotericin B, Lecture, Lower respiratory tract infection, Safety, Skin, Antimicrobial, Conference call, Abstract, Fungal infection, Survival, Partnership, Cell, Research, Hepatocellular carcinoma, BioNTech, Patient, Gene, Society, Histoplasmosis, Lung, Malignancy, Toxicity, Manuscript, Standard of care, Infection, Annual general meeting, Platinum, LNC, Pharmaceutical industry

BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.

Key Points: 
  • Conference call begins at 4:30 p.m. Eastern time today
    BEDMINSTER, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports financial results for the three months ending March 31, 2024 and provides a business update.
  • “We are highly encouraged by results from in vivo studies demonstrating a substantial reduction in the well-recognized toxicity of IV-docetaxel.
  • Subsequent to the close of the quarter, in April the Company raised gross proceeds of $10.0 million through a registered direct offering.
  • The live webcast will be accessible on the Investors section of the company’s website and archived for 90 days.

Aspira Women’s Health Announces Publication of Two OvaWatch Peer-Reviewed Manuscripts

Retrieved on: 
tisdag, maj 7, 2024
Ovarian cancer, Risk, Woman, Gynecologic Oncology (journal), Patient, Gynaecology, Manuscript, Artificial neural network, Risk assessment, Birth control

AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts.

Key Points: 
  • AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts.
  • The findings of this study demonstrate that use of OvaWatch® to stratify risk in patients with an adnexal mass might help to reduce surgical backlogs and unnecessary surgical referrals.
  • “Today, we mark the publication of additional clinical data to support the use of OvaWatch for the assessment of ovarian cancer risk for women with an adnexal mass,” said Nicole Sandford, Chief Executive Officer of Aspira.
  • Clinicians have long sought a better tool to develop an appropriate care plan for these women, and OvaWatch provides it.”
    “The publication of these manuscripts, along with last week’s announcement to make OvaWatch available for testing over time, is the latest example of Aspira keeping its promises to our stakeholders.

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Risk, Poster, Disease, LNP, Cell, Sangamo Therapeutics, MINT, Publication, AAV, DNA, Patient, Gene, Society, Genome, Manuscript, BioRxiv, Modularity, Annual general meeting, Therapy, Vaccine

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
  • Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
  • “Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field.
  • We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo.

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
tisdag, maj 7, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Research and development, ATS, Pulmonary hypertension, GOSS, Randomness, Security (finance), The Lancet, PAH, Conference, Orthostatic hypertension, Administration, Public expenditure, Entrepreneurship, Patient, Gossamer, Manuscript, Standard of care, American Thoracic Society, G&A, Pharmaceutical industry

Topline results from the PROSERA Study are expected in the fourth quarter of 2025.

Key Points: 
  • Topline results from the PROSERA Study are expected in the fourth quarter of 2025.
  • On May 6, Gossamer Bio and Chiesi Group announced a development and co-commercialization collaboration for seralutinib.
  • Gossamer and Chiesi will split global development costs for seralutinib, except for the PROSERA Study, for which Gossamer will remain solely responsible.
  • Financial Results for Quarter Ended March 31, 2024
    Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of March 31, 2024, were $244.4 million.

BostonGene and the Medical College of Wisconsin Announce the Publication and Journal Cover Feature in Gastroenterology Highlighting Transcriptomic-Based Tumor Microenvironment Classification for Precision Medicine in Pancreatic Cancer

Retrieved on: 
måndag, maj 6, 2024
Research, Genetics, Clinical Trials, Biotechnology, Health, University, Science, Education, Oncology, Cancer, Pancreas, Pancreatic cancer, MCW, Prognosis, Immunotherapy, Tumor microenvironment, Intelligence, Disease, Liver, Patient, Human, Fibrosis, Gene expression, Multimedia, Manuscript, Immune system, Medical director, Medical college, Gastrointestinal disease, TME, Pharmaceutical industry

BostonGene’s artwork was also chosen for the cover of the May publication.

Key Points: 
  • BostonGene’s artwork was also chosen for the cover of the May publication.
  • The journal highlights original research, reviews and expert insights in adult and pediatric gastroenterology and hepatology, covering clinical, translational and basic aspects of the digestive system, liver, pancreas and nutrition.
  • The study identified four distinct tumor microenvironment (TME) subtypes, unveiling a promising path forward in the fight against PDAC and underscoring the importance of considering TME features in personalized therapeutic strategies.
  • “For a long while, the scientific community believed that pancreatic cancer was not responsive to immunotherapy, which uses a person’s own immune system to fight cancer.

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

Retrieved on: 
tisdag, maj 7, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dicarboxylic acid, Metadata, DSM-IV codes, CRISPR, DOI, Safety, LAMA1, LAMA2, AAV, Tokyo Stock Exchange, DNA, Therapy, Patient, Congenital muscular dystrophy, Gene expression, Manuscript, BioRxiv, Vaccine

The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.

Key Points: 
  • The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.
  • LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein.
  • No approved therapies to address the root cause of this condition exist or are in clinical trials.
  • "We are thrilled to post our comprehensive preclinical data supporting the development of MDL-101 on bioRxiv.

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Retrieved on: 
fredag, maj 3, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Pulmonary hypertension, Safety, GOSS, Randomness, The Lancet, PAH, Heart, Disease, Patient, The, PVR, Manuscript, Quality of life, Orthostatic hypertension, Pharmaceutical industry

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal.

Key Points: 
  • Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal.
  • The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertension (TORREY): A Randomized, Double-blind, Placebo-controlled Phase 2 Trial," details the study's significant findings in advancing the treatment of PAH.
  • 86 patients were randomized to receive either seralutinib or placebo by dry powder inhaler twice daily for 24 weeks.
  • Details about PROSERA can be found here: https://clinicaltrials.gov/ct2/show/NCT05934526
    "The publication of the TORREY results in Lancet Respiratory Medicine represents a significant milestone in our ongoing commitment to addressing unmet medical needs for patients with pulmonary hypertension,” said Faheem Hasnain, CEO, Co-founder, and Chairman of Gossamer Bio.

Lindus Health and University of Oxford Publish Study Citing Key Strategies to Foster Diversity in Clinical Trial Participation

Retrieved on: 
torsdag, maj 2, 2024
FDA, MedRxiv, University, Social media, Safety, Risk, Research, EDICT, Manuscript, Clinical trial, Pharmaceutical industry

NEW YORK, May 2, 2024 /PRNewswire/ -- Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, announced the results of a study examining the motivators and deterrents of clinical trial participation among ethnic minorities. The research paper, published in MedRxiv, outlines strategies sponsors can utilize to minimize deterrents and promote diversity in their research.

Key Points: 
  • The research paper, published in MedRxiv , outlines strategies sponsors can utilize to minimize deterrents and promote diversity in their research.
  • Lindus Health partnered with the University of Oxford in a collaborative effort to conduct a qualitative study aimed at investigating perceptions regarding participation in clinical research.
  • The study collected data from both research professionals and the general population through eSurveys, meticulously crafted with guidance from the Enhancing Diversity in Clinical Trials (EDICT) advisory committee.
  • The top three barriers to participation overall, regardless of study phase, included safety and health concerns, time investment, and lack of support.

Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing

Retrieved on: 
torsdag, maj 2, 2024
Johns Hopkins University, University, Mayo Clinic, Cancer, SOS, American College, Case Western Reserve University, AUC, ACG, Esophageal cancer, Prevalence, Methylation, Risk, Barrett's esophagus, Cleveland Clinic, American Journal, Lucid, Adenocarcinoma, National Cancer Institute, NPV, NGS, University of North Carolina, Gold, Detection, EGD, Patient, Research report, NCI, PPV, Medicare, Manuscript, GERD, Guideline, Gastroesophageal reflux disease, Medical imaging

NEW YORK, May 2, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored, prospective, multicenter clinical validation study assessing the performance of Lucid's EsoGuard® Esophageal DNA Test on samples collected with its EsoCheck® Esophageal Cell Collection Device. This case-control study, led by Case Western Reserve University's Amitabh Chak, M.D., was funded through the NCI's Barrett's Esophagus Translational Research Network (BETRNet), and included renowned investigators from leading academic medical centers, including Case Western Reserve University, Mayo Clinic, Johns Hopkins University, Washington University in St. Louis, University of North Carolina, and Cleveland Clinic. EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD). The manuscript, entitled Multicenter, Prospective Trial of Non-Endoscopic Biomarker-Driven Detection of Barrett's Esophagus And Esophageal Adenocarcinoma, was published in the American Journal of Gastroenterology, the leading clinical journal covering gastroenterology published on behalf of the American College of Gastroenterology (ACG).

Key Points: 
  • EsoGuard demonstrated unprecedented early precancer detection compared to the gold standard of upper endoscopy (EGD).
  • Dr. Aklog concluded, "The publication of the BETRNet study is the culmination of a period of rapid expansion of EsoGuard's clinical evidence base.
  • It represents the second peer-reviewed, and third overall, clinical validation study demonstrating consistently excellent EsoGuard performance.
  • Soon to be released data from a fourth such clinical validation study tells the same story.